Lyra Therapeutics (LYRA) Q4 2025 earnings summary

Executive summary

• Suspended all development of lead product LYR-210 for chronic rhinosinusitis in January 2026 after prior workforce reductions and cost-saving actions following mixed Phase 3 trial results.

• Delisted from Nasdaq in March 2026 after ceasing operations and being deemed a public shell with no ongoing business activities.

• Ongoing evaluation of strategic alternatives, including potential merger, sale, or liquidation, with no assurance of a transaction.

Financial highlights

• Net loss for 2025 was $28.9 million, a significant improvement from $93.4 million in 2024, primarily due to reduced R&D and G&A expenses after restructuring.

• Cash and cash equivalents at year-end 2025 were $15.9 million, down from $40.6 million at year-end 2024.

• Operating expenses decreased to $31.4 million in 2025 from $97.9 million in 2024, reflecting lower clinical, personnel, and impairment costs.

• No impairment charges in 2025; 2024 included $1.9 million for property/equipment and $22.8 million for right-of-use assets.

• No product revenue; $0.4 million in collaboration revenue recognized in 2025 from the LianBio License Agreement.

Outlook and guidance

• No intention to resume R&D activities unless a strategic transaction or significant new funding is secured.

• Cash runway expected to last into Q3 2026, but subject to revision based on actual expenses and strategic outcomes.

• Ongoing costs expected for strategic review, consulting, and public company compliance during wind-down.